engraftment

The process where transplanted or edited stem cells successfully integrate into a patient's bone marrow and begin producing healthy new blood cells.

Engraftment is a critical clinical milestone in cell and gene therapies, as well as bone marrow transplants, where administered or edited stem cells successfully travel to the bone marrow, survive, and begin multiplying to produce new, functional blood cells. It marks the point at which a patient's body begins to rebuild its own blood and immune systems after undergoing intensive conditioning treatments like chemotherapy. In clinical trials, researchers measure the time to engraftment by tracking daily blood counts. Specifically, they monitor when key blood components—such as neutrophils (white blood cells) and platelets—rise above a predefined threshold and remain there for several consecutive days without the aid of transfusions. For biotechnology and pharmaceutical investors, engraftment data is a vital early indicator of a therapy's efficacy and safety. Successful and rapid engraftment validates the biological mechanism of the treatment, while delayed or failed engraftment (graft failure) poses severe clinical risks, including life-threatening infections or hemorrhages. Such failures can halt clinical trials, delay regulatory approvals, and severely damage a company's valuation.

In a clinical trial for a new gene therapy, a patient receives edited stem cells on Day 0. The trial protocol defines neutrophil engraftment as achieving an absolute neutrophil count (ANC) of 500 cells per microliter for three consecutive days. The patient's ANC measures 550 on Day 14, 610 on Day 15, and 580 on Day 16. The patient is recorded as having successfully engrafted on Day 14.